Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results.
Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results.
复制标题
苏拉明抗病毒治疗获得性免疫缺陷综合征。
DOI：
--
复制
发表时间：
1986
影响因子：
39.2
通讯作者：
S. Rasheed
中科院分区：
文献类型：
--
作者：
A. Levine;P. Gill;J. Cohen;J. Hawkins;S. Formenti;S. Aguilar;P. Meyer;M. Krailo;J. Parker;S. Rasheed
人类嗜t淋巴病毒III型/淋巴结病相关病毒（HTLV-III/LAV）需要逆转录酶进行病毒复制。我们用苏拉明（一种强效竞争性逆转录酶抑制剂）治疗12例获得性免疫缺陷综合征和活动性HTLV-III/LAV病毒血症患者，每周6次诱导剂量为1g，随后每周维持剂量为500mg。11名可评估的患者中有3名完全抑制了病毒逆转录酶水平，每位患者至少持续18周。另外两名患者的逆转录酶活性明显降低。诱导期结束时血清苏拉明水平与逆转录酶还原水平相关。毒性包括肝转氨酶升高、发热、不适、皮疹、蛋白尿、感觉异常、可逆性中性粒细胞减少和肾上腺功能不全。1例患者临床改善，但免疫功能无改善，7例患者复发机会性感染。虽然苏拉明可能抑制HTLV-III/LAV病毒血症，但其明显的毒性和对免疫变量的影响不足表明需要替代疗法。
The human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) requires reverse transcriptase for viral replication. We treated 12 patients who had acquired immunodeficiency syndrome and active HTLV-III/LAV viremia with suramin, a potent competitive inhibitor of reverse transcriptase, in six weekly induction doses of 1 g, followed by weekly maintenance doses of 500 mg. Three of eleven evaluable patients had complete inhibition of viral reverse transcriptase levels, lasting at least 18 weeks in each. Two additional patients had marked reduction in reverse transcriptase activity. Nadir serum suramin levels at the end of the induction phase correlated with the level of reverse transcriptase reduction. Toxicity included hepatic transaminase elevation, fever, malaise, rash, proteinuria, paresthesias, reversible neutropenia, and adrenal insufficiency. Objective clinical improvement was documented in 1 patient, but no patient had improvement in immune function and 7 patients had recurrent opportunistic infections. Although suramin may suppress HTLV-III/LAV viremia, its significant toxicity and lack of effect on immune variables indicate that alternative therapy will be required.
洛杉矶地区男同性恋者的病毒中和活性、血清学异质性和逆转录病毒分离。
影响因子：
3.7
作者：
Rasheed,S;Norman,GL;Gill,PS;Meyer,PR;Cheng,L;Levine,AM
通讯作者：
Levine,AM